Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/107612
DC FieldValueLanguage
dc.contributor.authorRodrigues-Santos, Paulo-
dc.contributor.authorLópez-Sejas, Nelson-
dc.contributor.authorAlmeida, Jani-Sofia-
dc.contributor.authorRuzičková, Lenka-
dc.contributor.authorCouceiro, Patrícia-
dc.contributor.authorAlves, Vera-
dc.contributor.authorCampos, Carmen-
dc.contributor.authorAlonso, Corona-
dc.contributor.authorTarazona, Raquel-
dc.contributor.authorFreitas-Tavares, Paulo-
dc.contributor.authorSolana, Rafael-
dc.contributor.authorSantos-Rosa, Manuel-
dc.date.accessioned2023-07-24T09:50:57Z-
dc.date.available2023-07-24T09:50:57Z-
dc.date.issued2018-
dc.identifier.issn1664-3224pt
dc.identifier.urihttps://hdl.handle.net/10316/107612-
dc.description.abstractNatural killer (NK) cells are a very important component of the innate immune response involved in the lysis of virus infected and tumor cells. Aging has a profound impact in the frequency, phenotype and function of NK cells. Chronic Myeloid Leukemia (CML) is caused by the BCR-ABL gene formation encoding aberrant oncoprotein tyrosine kinase. Treatment with tyrosine kinase inhibitors (TKIs) induces durable deep molecular response. The response to treatment and life expectancy is lower in older patients with chronic phase of CML than in younger patients. In this work we analyse NK cells from TKI-treated CML patients and healthy controls stratified according to age. We have analyzed the expression of NK receptors, activation markers, NK cell differentiation in CD56bright and CD56dim NK cell subsets and the expression of CD107a and IFN-γ in NK cells stimulated with K562. Whereas significant differences on the phenotype and function of NK cells were found between middle-aged (35-65 years old) and elderly (older than 65) healthy individuals, NK cells from TKI-treated CML patients do not show significant differences related with age in most parameters studied, indicating that age is not a limitation of the NK cell recovery after treatment with TKI. Our results also revealed differences in the expression of NK receptors, activation markers and functional assays in NK cells from TKI-treated CML patients compared with age-matched healthy controls. These results highlight the relevance of NK cells in TKI-treated patients and the need of an extensive analysis of the effect of aging on NK cell phenotype and function in these patients in order to define new NK-cell based strategies directed to control CML progression and achieve long-term disease remission after TKI cessation.pt
dc.language.isoengpt
dc.publisherFrontiers Media S.A.pt
dc.relationPOCI-01-0145-FEDER-007440pt
dc.relationprogram Iberoamerica Scholarships. Santander Research Santander Universities 2016–2017pt
dc.relationgrants PI13/02691 and PI16/01615 (to RS and CA) from Spanish Ministry ofHealthpt
dc.relationSAF2017-87538-R (to RT) from the Ministry of Economy and Competitiveness of Spainpt
dc.relationIB16164 and GR18085 from Junta de Extremadurapt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt
dc.subjectagingpt
dc.subjectCMLpt
dc.subjectNK receptorspt
dc.subjectactivation markerspt
dc.subjectdifferentiation markerspt
dc.subjectcytokinespt
dc.subjectNK cell subsetspt
dc.subjecttyrosine kinase inhibitorspt
dc.subject.meshAdultpt
dc.subject.meshAgedpt
dc.subject.meshAged, 80 and overpt
dc.subject.meshAgingpt
dc.subject.meshAntineoplastic Agentspt
dc.subject.meshCell Differentiationpt
dc.subject.meshFemalept
dc.subject.meshGenes, ablpt
dc.subject.meshHumanspt
dc.subject.meshK562 Cellspt
dc.subject.meshKiller Cells, Naturalpt
dc.subject.meshLeukemia, Myelogenous, Chronic, BCR-ABL Positivept
dc.subject.meshLymphocyte Activationpt
dc.subject.meshMalept
dc.subject.meshMiddle Agedpt
dc.subject.meshProtein Kinase Inhibitorspt
dc.subject.meshTreatment Outcomept
dc.subject.meshAge Factorspt
dc.titleEffect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitorspt
dc.typearticle-
degois.publication.firstPage2587pt
degois.publication.titleFrontiers in Immunologypt
dc.peerreviewedyespt
dc.identifier.doi10.3389/fimmu.2018.02587pt
degois.publication.volume9pt
dc.date.embargo2018-01-01*
uc.date.periodoEmbargo0pt
item.grantfulltextopen-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.openairetypearticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextCom Texto completo-
crisitem.author.orcid0000-0002-7185-9336-
crisitem.author.orcid0000-0001-7832-4134-
crisitem.author.orcid0000-0003-0789-8637-
Appears in Collections:I&D CNC - Artigos em Revistas Internacionais
FMUC Medicina - Artigos em Revistas Internacionais
Show simple item record

SCOPUSTM   
Citations

4
checked on May 6, 2024

WEB OF SCIENCETM
Citations

2
checked on May 2, 2024

Page view(s)

78
checked on May 7, 2024

Download(s)

19
checked on May 7, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons